| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S87870-1mg促销 |
≥97% | ￥300.00 ￥270.00 |
10 | - | - | - | - |
|
S87870-5mg促销 |
≥97% | ￥1000.00 ￥900.00 |
8 | - | - | - | - |
|
S87870-25mg促销 |
≥97% | ￥3000.00 ￥2700.00 |
4 | - | - | - | - |
|
S87870-50mg促销 |
≥97% | ￥5000.00 ￥4500.00 |
2 | - | - | - | - |
|
| 产品描述： | Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | EC50: 2.2/1.0 μM (HCV 1a/1b) | ||||||||||||||||||||
| 体外研究： | Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 µM, and EC90s of 8.0 and 6.0 µM for genotype 1A and 1B, respectively. Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense | ||||||||||||||||||||
| 体内研究： | The induction of host immune responses by pretreatment with Inarigivir soproxil (SB 9200) followed by Entecavir (ETV) resulted in antiviral efficacy that was superior to that obtained using the strategy of viral reduction with ETV followed by immunomodulation. Sequential treatment of chronic WHV carrier woodchucks with Inarigivir soproxil (30 mg/kg)followed by ETV induced marked suppression of serum viremia and antigenemia and delayed recrudescence of viral replication compared to sequential treatment with ETV followed by Inarigivir soproxil. Animal Model: Woodchucks chronically infected with woodchuck hepatitis virus (WHV) Dosage: 30 mg/kg Administration: Orally treated once daily; group 1 received ETV for 4 weeks followed by Inarigivir soproxil for 12 weeks. Group 2 received Inarigivir soproxil for 12 weeks followed by ETV for 4 weeks Result: Both groups demonstrated marked reductions in hepatic WHV nucleic acid levels which were more pronounced in Group 2. | ||||||||||||||||||||
| 参考文献： | 1. Meleri Jones, et al. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628. 2. Manasa Suresh, et al. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017 Jan 5;12(1):e0169631. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO、H2O | ||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京